(R)-8-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-hexahydro-pyrazino[2,1-c][1,4]oxazin-4-one | 1147422-43-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: (R)-8-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-hexahydro-pyrazino[2,1-c][1,4]oxazin-4-one
• 英文别名: (9aR)-8-[(2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl)methyl]-6,7,9,9a-tetrahydro-1H-pyrazino[2,1-c][1,4]oxazin-4-one
• CAS: 1147422-43-2
• 化学式: C₁₈H₂₂ClN₅O₃S
• 分子量: 423.923
• InChiKey: JQKHDYNRIXETAC-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  99.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (S)-4-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-3-isopropyl-piperazin-2-one 、 (R)-六氢[2,1-C][1,4]噁嗪-4(3H)-酮 以The title compound was obtained as a tan solid (79 mg, 69%)的产率得到(R)-8-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-hexahydro-pyrazino[2,1-c][1,4]oxazin-4-one
  参考文献：
  名称：

  THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS

  摘要：

  公式（I）中，W和R1至R4的定义如索权所述，其药学上可接受的盐是PI3K的抑制剂，并且选择性地作用于p110δ同工酶，该同工酶是一种Ia类PI3激酶，优于其他Ia类和Ib类激酶。这些化合物可用于治疗由PI3激酶引起的异常细胞生长、功能或行为所引起的疾病和障碍，如癌症、免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌功能障碍和神经系统障碍。

  公开号：

  US20110021496A1

文献信息

• Thienopyrimidine derivatives as P13K inhibitors
  申请人：F. Hoffmann-La Roche AG

  公开号：US08293735B2

  公开（公告）日：2012-10-23

  Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

  公式（I）中W和R1至R4的定义如权利要求中所述，其药学上可接受的盐是PI3K的抑制剂，并且对于p110δ异构体具有选择性，该异构体是Ia类PI3激酶，优于其他Ia类和Ib类激酶。这些化合物可用于治疗由于PI3激酶引起的异常细胞生长，功能或行为而引起的疾病和障碍，如癌症，免疫障碍，心血管疾病，病毒感染，炎症，代谢/内分泌功能障碍和神经系统障碍。
• US8293735B2
  申请人：——

  公开号：US8293735B2

  公开（公告）日：2012-10-23
• [EN] THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE THIÉNOPYRIMIDIÈNE COMME INHIBITEURS DE PI3K
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009053715A1

  公开（公告）日：2009-04-30

  Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.